Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Corvus Pharmaceuticals, Inc. (CRVS : NSDQ)

• Company Description    Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. Number of Employees: 28

• Price / Volume Information    Yesterday's Closing Price: $1.04 Daily Weekly Monthly 20 Day Moving Average: 230,680 shares Shares Outstanding: 46.55 (millions) Market Capitalization: $48.65 (millions) Beta: 1.06 52 Week High: $9.54 52 Week Low: $1.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -24.82% -17.68% 12 Week -43.21% -36.17% Year To Date -56.64% -47.03%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 863 Mitten Road Suite102 - BURLINGAME,CA 94010 USA ph: 650-900-4520 fax: - jcoloma@corvuspharma.com http://www.corvuspharma.com

• General Corporate Information    Officers Richard A. Miller - President; Chief Executive Officer and Director Leiv Lea - Chief Financial Officer Ian T. Clark - Director Linda S. Grais - Director Edith P. Mitchell - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 221015100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/01/22 Share - Related Items Shares Outstanding: 46.55 Most Recent Split Date: (:1) Beta: 1.06 Market Capitalization: $48.65 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.88 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/01/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.54 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 47.06% vs. Previous Quarter: 10.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -41.15 12/31/21 - -44.00 09/30/21 - -47.94 ROA 03/31/22 - -36.37 12/31/21 - -38.66 09/30/21 - -41.67 Current Ratio 03/31/22 - 6.95 12/31/21 - 7.36 09/30/21 - 6.97 Quick Ratio 03/31/22 - 6.95 12/31/21 - 7.36 09/30/21 - 6.97 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 1.93 12/31/21 - 2.09 09/30/21 - 2.48 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©